A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]

ClinicalTrials.gov ID: NCT05565742

Public ClinicalTrials.gov record NCT05565742. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 28, 2026, 8:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3819469 in Adults With Elevated Lipoprotein(a)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The main purpose of this study is to determine the efficacy and safety of LY3819469 in adults with elevated lipoprotein(a). The study will lasts about 20 months.

Study identification

NCT ID: NCT05565742
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Eli Lilly and Company; Industry
Enrollment: 320 participants

Conditions and interventions

Conditions

Lipoprotein Disorder

Interventions

LY3819469 Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 40 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 20, 2022 (Actual)
Primary completion: Oct 23, 2023 (Actual)
Completion: Oct 17, 2024 (Actual)
Last update posted: May 28, 2025

2022 – 2024

United States locations

U.S. sites: 19
U.S. states: 11
U.S. cities: 19

Facility	City	State	ZIP	Site status
Care Access - 801 South Power Road, Mesa	Mesa	Arizona	85206	—
Care Access - South Pasadena	Pasadena	California	91105	—
Care Access - Santa Clarita	Santa Clarita	California	91321	—
Care Access - Spring Hill	Spring Hill	Florida	34609	—
Care Access - Pebble Beach Boulevard, Tampa	Sun City	Florida	33573	—
Care Access - Tamarac	Tamarac	Florida	33321	—
Care Access - Tampa	Tampa	Florida	33625	—
Care Access - Lake Charles	Lake Charles	Louisiana	70601	—
Care Access - Baltimore	Baltimore	Maryland	21213	—
Care Access - Dorchester	Dorchester	Massachusetts	02124	—
Aventiv Research Inc	Columbus	Ohio	43213	—
Care Access - Lima	Lima	Ohio	45805	—
Capital Area Research, LLC	Camp Hill	Pennsylvania	17011	—
Lancaster General Hospital	Lancaster	Pennsylvania	17602	—
Cardiology Consultants of Philadelphia Yardley	Yardley	Pennsylvania	19067	—
Care Access - Rapid City	Rapid City	South Dakota	57701	—
Care Access - Georgetown	Georgetown	Texas	78633	—
Care Access - Katy	Katy	Texas	77450	—
Virginia Heart	Falls Church	Virginia	22042	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 61 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05565742, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 28, 2025 · Synced Oct 28, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT05565742 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →